Express Scripts Holding Co (ESRX) Expected to Announce Quarterly Sales of $24.90 Billion
Wall Street analysts predict that Express Scripts Holding Co (NASDAQ:ESRX) will report $24.90 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Twelve analysts have issued estimates for Express Scripts’ earnings, with the highest sales estimate coming in at $25.16 billion and the lowest estimate coming in at $24.53 billion. Express Scripts reported sales of $24.68 billion in the same quarter last year, which indicates a positive year-over-year growth rate of 0.9%. The business is expected to report its next quarterly earnings report on Tuesday, October 23rd.
According to Zacks, analysts expect that Express Scripts will report full-year sales of $100.91 billion for the current fiscal year, with estimates ranging from $99.82 billion to $101.47 billion. For the next year, analysts forecast that the company will report sales of $103.37 billion per share, with estimates ranging from $99.76 billion to $106.53 billion. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Express Scripts.
Express Scripts (NASDAQ:ESRX) last released its earnings results on Wednesday, August 1st. The company reported $2.22 EPS for the quarter, topping analysts’ consensus estimates of $2.20 by $0.02. The company had revenue of $25.64 billion for the quarter, compared to the consensus estimate of $25.43 billion. Express Scripts had a return on equity of 25.49% and a net margin of 4.65%. Express Scripts’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.73 EPS.
In related news, insider Christine Houston sold 12,898 shares of the firm’s stock in a transaction that occurred on Friday, August 10th. The stock was sold at an average price of $85.00, for a total value of $1,096,330.00. Following the sale, the insider now directly owns 110,908 shares in the company, valued at approximately $9,427,180. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.79% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Landaas & Co. WI ADV acquired a new stake in Express Scripts in the 2nd quarter valued at approximately $102,000. Kaizen Advisory LLC increased its position in shares of Express Scripts by 147.6% during the 2nd quarter. Kaizen Advisory LLC now owns 1,342 shares of the company’s stock valued at $104,000 after purchasing an additional 800 shares during the period. Wealthcare Advisory Partners LLC increased its position in shares of Express Scripts by 364.7% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 1,529 shares of the company’s stock valued at $106,000 after purchasing an additional 1,200 shares during the period. Adviser Investments LLC increased its position in shares of Express Scripts by 321.9% during the 2nd quarter. Adviser Investments LLC now owns 1,481 shares of the company’s stock valued at $114,000 after purchasing an additional 1,130 shares during the period. Finally, Sun Life Financial INC increased its position in shares of Express Scripts by 758.8% during the 2nd quarter. Sun Life Financial INC now owns 1,520 shares of the company’s stock valued at $117,000 after purchasing an additional 1,343 shares during the period. Hedge funds and other institutional investors own 84.52% of the company’s stock.
Shares of NASDAQ ESRX traded up $0.61 during mid-day trading on Wednesday, hitting $88.00. The company had a trading volume of 3,973,800 shares, compared to its average volume of 4,358,478. The company has a market cap of $47.02 billion, a price-to-earnings ratio of 12.34, a price-to-earnings-growth ratio of 1.05 and a beta of 0.95. Express Scripts has a 12 month low of $55.80 and a 12 month high of $88.30. The company has a current ratio of 0.71, a quick ratio of 0.59 and a debt-to-equity ratio of 0.69.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Further Reading: Average Daily Trade Volume Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.